In a perspective piece, Kori Wallace, AbbVie’s VP of Clinical Development for Immunology, outlines a strategic shift toward precision immunology built on reverse translation and rational combination strategies. AbbVie argues that leveraging clinical datasets and molecular profiling can close gaps between discovery and durable patient responses across immune‑mediated diseases. Wallace emphasizes integrating real-world evidence, biomarker-driven trial design, and combination approaches to break efficacy plateaus in immunology. The perspective signals how large immunology players are sharpening development playbooks to target molecular drivers and reduce trial unpredictability.